Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Cash and Equivalents of $743.29 million for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $743.29M | +25.1% |
| 2024 | $594.35M | +51.8% |
| 2023 | $391.56M | -28.8% |
| 2022 | $549.91M | +92.9% |
| 2021 | $285.12M | +8.8% |
| 2020 | $262.13M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $659.84M | +54.3% | +25.7% |
| June 30, 2025 | $525.11M | +10.7% | +4.9% |
| March 31, 2025 | $500.45M | +68.9% | -15.8% |
| December 31, 2024 | $594.35M | +51.8% | +39.0% |
| September 30, 2024 | $427.65M | +10.4% | -9.8% |
| June 30, 2024 | $474.34M | +16.9% | +60.1% |
| March 31, 2024 | $296.33M | -37.4% | -24.3% |
| December 31, 2023 | $391.56M | -28.8% | +1.1% |
- RECURSION PHARMACEUTICALS, INC. showed an increase of +25.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, RECURSION PHARMACEUTICALS, INC.’s cash and equivalents has grown by 183.6% (from $262.13 million to $743.29 million).
- The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: